纳武利尤单抗相关获得性脂肪营养不良一例
本文报告一例晚期肾细胞癌女性患者,在接受纳武利尤单抗治疗2个月后出现面部及颈部、肩部、手臂和臀部脂肪萎缩,糖尿病控制恶化。皮下活检示慢性小叶性脂膜炎,提示获得性全身性脂肪营养不良可能与该抗PD-1治疗相关。
要点
- 抗PD-1治疗可能诱发获得性脂肪营养不良,需早期识别。
- 脂肪萎缩可表现为面部脂肪垫丢失及肢体脂肪减少。
- 出现不明原因脂肪萎缩时应追问免疫检查点抑制剂用药史。
核心结论
- 抗PD-1治疗具有很大潜力,但早期识别不寻常的不良反应对肿瘤患者治疗决策很重要。
研究设计与样本
- 病例报告:一例晚期肾细胞癌女性患者,50岁诊断2型糖尿病,2010年诊断肾透明细胞癌,2017年开始纳武利尤单抗治疗。
主要发现
- 纳武利尤单抗治疗2个月后出现面部脂肪萎缩,颊脂肪垫丢失及颧弓突出,颈部、肩部、手臂和臀部也受累。
- 糖尿病控制恶化,需最大剂量二甲双胍和吡格列酮,并给予1.5单位/kg/天胰岛素。
- 手臂内侧皮下活检显示慢性小叶性脂膜炎。
- 因观察到癌症进展减缓且无替代化疗,继续纳武利尤单抗治疗 justified;治疗8个月后因3级肝炎停药。
临床怎么用
- 使用抗PD-1治疗的患者出现脂肪萎缩或糖尿病控制恶化时,应考虑获得性脂肪营养不良的可能。
局限性
- 为单例病例报告,不能确立纳武利尤单抗与脂肪营养不良的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Lipodystrophy syndromes are rare disorders characterized by the selective loss of adipose tissue. We aimed to report a case of acquired generalized lipodystrophy possibly associated with nivolumab. CASE DESCRIPTION: A woman was referred to our Endocrinology Department for uncontrolled diabetes mellitus. At 50 years of age, she was diagnosed with type 2 diabetes after a routine laboratory test and her diabetes was well controlled with low doses of metformin. In 2010, she was diagnosed with clear cell renal carcinoma. The cancer progressed in the following years, leading to the initiation of treatment with nivolumab in 2017. Two months later she presented with facial lipoatrophy, with loss of the buccal fat pads and prominent zygomatic arch. Her neck, shoulders, arms, and buttocks were also affected. Her diabetes control worsened. She received maximal doses of metformin and pioglitazone and was administered 1.5 units/kg/d insulin. Subcutaneous biopsy of medial surface of the arm revealed chronic lobular panniculitis. Despite nivolumab's possible involvement in the onset of lipodystrophy, the maintenance of nivolumab therapy was justified by the observed reduction in the progression of the cancer, combined with the lack of an alternative chemotherapy. The therapy was withdrawn after 8 months of treatment because of grade 3 hepatitis. CONCLUSION: Anti-PD1 therapy has great potential. Early recognition of the onset of unusual collateral effects is important to improve decision making regarding the treatment of patients with tumors.
引用
- Falcao CK, Cabral MCS, Mota JM, et al. Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma. J Clin Endocrinol Metab. 2019. PMID: 30779841. doi:10.1210/jc.2018-02221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。